Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Public ClinicalTrials.gov record NCT03192397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Study identification
- NCT ID
- NCT03192397
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Enrollment
- 35 participants
Conditions and interventions
Conditions
- Acute Myeloid Leukemia in Remission
- Adult Acute Lymphoblastic Leukemia in Complete Remission
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
- Chronic Myelomonocytic Leukemia in Remission
- Graft Versus Host Disease
- Hodgkin Lymphoma
- Minimal Residual Disease
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Plasma Cell Myeloma
- Severe Aplastic Anemia
- Waldenstrom Macroglobulinemia
Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Cyclophosphamide Drug
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Melphalan Hydrochloride Drug
- Mycophenolate Mofetil Drug
- Sirolimus Drug
- Total-Body Irradiation Radiation
Procedure · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2017
- Primary completion
- Aug 20, 2023
- Completion
- May 20, 2027
- Last update posted
- Apr 13, 2026
2017 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03192397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03192397 live on ClinicalTrials.gov.